- Home
- VSTM vs MIST Comparison
VSTM vs MIST Comparison
Compare VSTM & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | MIST |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 176.3M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | VSTM | MIST |
|---|---|---|
| Price | $8.06 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $13.38 | $8.50 |
| AVG Volume (30 Days) | 1.7M | ★ 10.1M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,379,000.00 | N/A |
| Revenue This Year | $208.54 | N/A |
| Revenue Next Year | $251.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.79 | N/A |
| 52 Week Low | $3.46 | $0.63 |
| 52 Week High | $11.25 | $3.06 |
Technical Indicators
Market Signals| Indicator | VSTM | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 42.75 |
| Support Level | $7.59 | $1.90 |
| Resistance Level | $8.23 | $2.22 |
| Average True Range (ATR) | 0.56 | 0.33 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 15.64 | 33.20 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).